M&A / Deals Incyte gobbles up Star’s Vega haematology unit in $2bn deal PharmaphorumIncyte has agreed to buy Star Therapeutics' Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD.HematologyRead full story pharminent June 8, 2026 (Last updated: June 8, 2026) Pharmaphorum Incyte has agreed to buy Star Therapeutics’ Vega subsidiary for $1.25bn upfront, adding a late-stage drug candidate for bleeding disorder VWD. Hematology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche doubles down on BTK with $2.3bn Nurix dealNext: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
